Patents Assigned to Altor Bioscience Corporation
-
Patent number: 10450359Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: September 1, 2016Date of Patent: October 22, 2019Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 10358478Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: July 19, 2016Date of Patent: July 23, 2019Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9925247Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.Type: GrantFiled: June 30, 2015Date of Patent: March 27, 2018Assignee: Altor Bioscience CorporationInventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
-
Patent number: 9714279Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).Type: GrantFiled: December 4, 2014Date of Patent: July 25, 2017Assignee: Altor Bioscience CorporationInventors: Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
-
Patent number: 9593152Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: December 12, 2014Date of Patent: March 14, 2017Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9464127Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: July 19, 2013Date of Patent: October 11, 2016Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9428573Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: July 19, 2013Date of Patent: August 30, 2016Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9328159Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).Type: GrantFiled: April 1, 2013Date of Patent: May 3, 2016Assignee: Altor Bioscience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 9290560Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.Type: GrantFiled: February 18, 2014Date of Patent: March 22, 2016Assignee: ALTOR BIOSCIENCE CORPORATIONInventors: Shari A. Price-Schiavi, Heather J. Belmont, Kimberlyn F. Card, Xiaoyun Zhu, Hing C. Wong
-
Patent number: 8940289Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: March 23, 2012Date of Patent: January 27, 2015Assignee: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 8933198Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQL (SEQ ID NO: 1)).Type: GrantFiled: March 25, 2010Date of Patent: January 13, 2015Assignee: Altor BioScience CorporationInventors: Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
-
Publication number: 20140378656Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.Type: ApplicationFiled: February 18, 2014Publication date: December 25, 2014Applicant: ALTOR BIOSCIENCE CORPORATIONInventors: Shari A. Price-Schiavi, Heather J. Belmont, Kimberlyn F. Card, Xiaoyun Zhu, Hing C. Wong
-
Publication number: 20140242025Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).Type: ApplicationFiled: February 15, 2013Publication date: August 28, 2014Applicant: ALTOR BIOSCIENCE CORPORATIONInventors: HING C. WONG, PETER RHODE, BAI LIU, XIAOYUN ZHU, KAI-PING HAN
-
Publication number: 20140219955Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: ApplicationFiled: July 19, 2013Publication date: August 7, 2014Applicant: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20140205560Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: ApplicationFiled: July 19, 2013Publication date: July 24, 2014Applicant: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 8772451Abstract: Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.Type: GrantFiled: November 10, 2004Date of Patent: July 8, 2014Assignee: Altor BioScience CorporationInventors: Shari A. Price-Schiavi, Heather J. Belmont, Kimberlyn F. Card, Xiaoyun Zhu, Hing C. Wong
-
Patent number: 8507222Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.Type: GrantFiled: September 21, 2011Date of Patent: August 13, 2013Assignee: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
-
Patent number: 8492118Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: May 9, 2008Date of Patent: July 23, 2013Assignee: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20130115191Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.Type: ApplicationFiled: September 12, 2012Publication date: May 9, 2013Applicant: ALTOR BIOSCIENCE CORPORATIONInventors: Jon A. Weidanz, Kimberlyn F. Card, Hing C. Wong
-
Publication number: 20120230995Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: ApplicationFiled: December 22, 2011Publication date: September 13, 2012Applicant: Altor BioScience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong